ODI PHARMA AB
NNGM:ODI1.46
SEK
+0.09
(+6.57%)
ISIN
SE0013409760
Return %
Stock
S&P 500
1Y
-1.35
14.20
3Y
-69.90
81.12
5Y
-77.43
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Jan-Mark Edewaard
- Full Time Employees
- 1
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Östermalmstorg 1 Stockholm AB Sweden 114 42
- IPO Date
- Jan 23, 2020
- Website
- odipharma.com
- Similar Companies
- Business
- ODI Pharma AB (publ), a Swedish pharmaceutical company founded in 2018 and headquartered at Oestermalmstorg 1 in Stockholm, specializes in the production and distribution of medical cannabis products and cosmetics across Europe, primarily targeting Eastern European medicinal markets through subsidiaries such as ODI Pharma Polska Sp. z o.o. and partnerships with wholesale distributors serving over 14,000 pharmacies, specialty clinics, and hospitals. The company offers pharmaceutical-grade dried cannabis flowers featuring varying THC and CBD levels for treating conditions including multiple sclerosis, chronic pain, and chemotherapy side effects; cannabis oils, capsules, tablets, and oromucosal sprays; and cosmetics under the Kandol brand, sourcing raw materials from global leaders like Tilray Brands Inc. to ensure quality and regulatory compliance without in-house cultivation. Recent developments include an exclusive supply collaboration with Synoptis Pharma Sp. z o.o., part of Poland's Neuca Group, positioning ODI as the primary medicinal cannabis provider in Poland and 22 other Eastern and Southeastern European countries following regulatory approval and a near-doubling of Poland's 2025 import quota; a January 2025 CEO appointment of Jan-Mark Edewaard; sale of the Kandol skincare brand for SEK 3.2 million; a rights issue raising approximately SEK 2.2 million net; and loan financing of EUR 350,000 to support expansion and financial strengthening.